A Phase 2 interventional study of Eltrombopag and Dexamethasone in Immune Thrombocytopenia (ITP), sponsored by Novartis Pharmaceuticals. Completed at 10 sites in Germany. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-05-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 26th largest by enrollment, is one of 3 that started in 2020, is one of 15 in phase 2, and was the 27th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:
Sohag University · Sites in Egypt
Ages 18–75
Renata PLC · Sites in Bangladesh
Ages 18–70
Nahda University · Sites in Egypt
Ages 18–65
Novartis Pharmaceuticals
Ages 5–17
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–80
By country, each count listing its studies:
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 16 · Phase 3 9 · Phase 4 5
First in 2005; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 40 across the 36 interventional studies. Of the 25 that completed or were terminated, 14 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,720 studies on the registry; 221 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis: 4 open now, 7 under way, 2 of them phase 3. Of 7 finished, 6 (86%) have results posted.
Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, this one is the 8th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2020, is one of 7 in phase 2, and was the 5th registered.
Novartis’s Purpura, Thrombocytopenic, Idiopathic studies by the year they started, since 2006.
1 of the studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07189910Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP | 2027-11-01 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 17 in Purpura, Thrombocytopenic, Idiopathic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to compare the ability of eltrombopag in combination with a short course of high-dose dexamethasone to induce sustained response off treatment in patients with newly-diagnosed ITP versus 1-3 cycles of dexamethasone monotherapy.
The unmet clinical need and the potential for eltrombopag when added to steroids to improve the treatment outcome and the potential to induce sustained response off treatment serve as the basis for clinical investigation of eltrombopag in first-line ITP.
This is a Phase II, multicenter, 1:1 randomized, open-label study that compared the efficacy and safety of eltrombopag in combination with a short course of high-dose dexamethasone to 1-3 cycles of high-dose dexamethasone monotherapy, as first-line treatment in adult patients with newly diagnosed ITP.
Adult patients with newly diagnosed ITP who had platelet counts \< 30 × 10\^9/L and required treatment were screened, and if eligible, were randomized to either Arm A (eltrombopag in combination with a short course of dexamethasone) or Arm B (1-3 cycles of dexamethasone monotherapy).
The study was conducted in the following periods:
Screening Period: Patients were screened for 14 days based on the inclusion and exclusion criteria.
Treatment Period: Arm A: Patients were treated for 26 weeks during the treatment period. Patients who reached platelet counts ≥ 30 × 10\^9/L and maintained counts ≥ 30 × 10\^9/L during the tapering phase were eligible for treatment discontinuation. Duration of tapering before treatment discontinuation at Week 26 was 6 weeks. Arm B: Patients were treated up to 12 weeks during the treatment period. Patients who reached platelet counts ≥ 30 × 10\^9/L and maintained counts ≥ 30 × 10\^9/L after 1-3 cycles of dexamethasone treatment were eligible for treatment discontinuation. Patients with platelet counts \< 30 × 10\^9/L after 3 cycles of dexamethasone treatment were offered a course of eltrombopag treatment within the study and were discontinued from study at week 52.
Observation period: After completion of the treatment period, all patients were observed for sustained response off treatment until week 52. Only patients with sustained response at week 52 were followed for another 26 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients were treated with eltrombopag in combination with a standard high-dose dexamethasone (1 cycle: 40 mg once daily (QD) from day 1-4) to induce sustained response off treatment.
Drug: Eltrombopag · Drug: Dexamethasone
Patients were treated with a standard high-dose dexamethasone (1-3 cycles: 40 mg QD day 1-4 at 4 weeks intervals (or at 14-28 days intervals if needed) to induce sustained response off treatment.
Drug: Dexamethasone
Eltrombopag is for oral use and comes in 25, 50 and 75 mg tablets. Prescribed dose is taken once daily.
Also known as: ETB115
Dexamethasone is for oral use and comes in 8 mg tablets. Prescribed dose is taken once daily.
Percentage of Patients With Sustained Response Off Treatment at 52 Weeks
Sustained response off treatment at 52 weeks is defined as maintenance of platelet count ≥ 30 × 10\^9/L after treatment discontinuation until Week 52 in the absence of bleeding events ≥ Grade II or use of any rescue medication at all visits until Week 52. Bleeding events ≥ Grade II are assessed by the modified World Health Organization (WHO) Bleeding Scale; Bleeding is graded based on a 1-4 scale (1=minor bleeding to 4=severe bleeding). Characteristics of bleeding events ≥ Grade II include: epistaxis ≥30 minutes, large purpura, joint bleeding, melanotic stool, hematemesis, gross hematuria, abnormal vaginal bleeding, hemoptysis, Visible blood in body cavity fluid, retinal bleeding, bleeding at invasive sites, bleeding requiring transfusion, bleeding associated with moderate or severe hemodynamic instability, fatal bleeding, CNS bleeding.
Time frame: Study treatment discontinuation until week 52
Percentage of Patients With Overall Response at Week 52
Overall response after treatment at week 52 was defined as maintenance of platelet count ≥ 30 x 109/L and ≥ 2-fold increase of screening platelet count after treatment discontinuation in the absence of bleeding event ≥ Grade II and no rescue therapy at all visits until Week 52. Bleeding events ≥ Grade II are assessed by the modified World Health Organization (WHO) Bleeding Scale; Bleeding is graded based on a 1-4 scale (1=minor bleeding to 4=severe bleeding). Characteristics of bleeding events ≥ Grade II include: epistaxis ≥30 minutes, large purpura, joint bleeding, melanotic stool, hematemesis, gross hematuria, abnormal vaginal bleeding, hemoptysis, Visible blood in body cavity fluid, retinal bleeding, bleeding at invasive sites, bleeding requiring transfusion, bleeding associated with moderate or severe hemodynamic instability, fatal bleeding, CNS bleeding.
Time frame: Study treatment discontinuation until week 52
Duration of Sustained Response Off Treatment
Duration of sustained response off treatment is defined as time of treatment discontinuation until platelet count \< 30 × 109/L or bleeding events ≥ Grade II or use of any rescue therapy. If sustained response remains, the interval was censored with the date of the last platelet assessment. Bleeding events ≥ Grade II are assessed by the modified World Health Organization (WHO) Bleeding Scale; Bleeding is graded based on a 1-4 scale (1=minor bleeding to 4=severe bleeding). Characteristics of bleeding events ≥ Grade II include: epistaxis ≥30 minutes, large purpura, joint bleeding, melanotic stool, hematemesis, gross hematuria, abnormal vaginal bleeding, hemoptysis, Visible blood in body cavity fluid, retinal bleeding, bleeding at invasive sites, bleeding requiring transfusion, bleeding associated with moderate or severe hemodynamic instability, fatal bleeding, CNS bleeding.
Time frame: from last dose of study treatment until loss of response, approx. 52 weeks
Overall Response by Week 4
Overall response by week 4 is defined as platelet count ≥ 30 × 109/L and ≥ 2 fold increase of screening platelet count and absence of bleeding and no rescue therapy within the first 4 weeks
Time frame: By Week 4
Complete Response by Week 4
Complete Response by week 4 is defined as platelet count ≥ 100 × 109/L and absence of bleeding and no rescue therapy until week 4.
Time frame: By Week 4
Absolute Change in Platelet Count From Pre-treatment/Screening to Baseline and to Various Time Points
Absolute change in platelet count from pre-treatment or screening to baseline (week 1) and from pre-treatment / screening to 2, 4, 13, 27 and 53 weeks. If pre-treatment was necessary before inclusion, platelet count data performed directly before pre-treatment were used for study inclusion (screening value to be used for inclusion/exclusion check and for analysis as a covariate).
Time frame: Pre-treatment/screening, Week 1 (baseline), 2, 4, 13, 27, and 53
Relative Change in Platelet Count From Pre-treatment/Screening to Baseline and to Various Time Points
Relative change in platelet count from pre-treatment or screening to baseline (week 1) and from pre-treatment or screening to 2, 4, 13, 27, and 53 weeks. If pre-treatment was necessary before inclusion, platelet count data performed directly before pre-treatment were used for study inclusion (screening value to be used for inclusion/exclusion check and for analysis as a covariate).
Time frame: Pre-treatment/screening, Week 1 (baseline), 2, 4, 13, 27, and 53
Time to Overall Response (TOR)
Time to overall response is defined as time from starting study treatment to time of achievement of overall response. Overall response is defined as a platelet count ≥ 30 × 10\^9/L and ≥ 2 fold increase of baseline platelet count and absence of bleeding and no rescue therapy censored with the last visit date for patients not achieving overall response. Results of TOR are reported per Kaplan-Meier estimates.
Time frame: Time from starting study treatment to achievement of complete response (up to 52 weeks)
Time to Complete Response
Time to complete response is defined as time from starting study treatment to time of achievement of complete response. Complete response is defined as a platelet count ≥ 100 × 109/L and absence of bleeding and no rescue therapy. Results of time to complete response are reported per Kaplan-Meier estimates.
Time frame: Time from starting study treatment to achievement of complete response (up to 52 weeks)
Duration of Overall Response (OR) and Complete Response (CR)
Duration of overall or complete response (CR) is defined as time of achievement of overall or CR until loss of overall or CR. The duration of CR was calculated from the date of onset of CR until platelet count \< 100 x 109/L, or bleeding events ≥ Grade II (assessed by the modified World Health Organization (WHO) Bleeding Scale) or use of any rescue therapy, whatever was earlier. Bleeding is graded based on a 1-4 scale (1=minor bleeding to 4=severe bleeding). Characteristics of bleeding events ≥ Grade II include: epistaxis ≥30 minutes, large purpura, joint bleeding, melanotic stool, hematemesis, gross hematuria, abnormal vaginal bleeding, hemoptysis, Visible blood in body cavity fluid, retinal bleeding, bleeding at invasive sites, bleeding requiring transfusion, bleeding associated with moderate or severe hemodynamic instability, fatal bleeding, CNS bleeding. Results of duration of overall and complete response are reported per Kaplan-Meier estimates.
Time frame: Achievement of overall or complete response until loss of response (up to 52 weeks)
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Questionnaire
The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) instrument is a 13-item validated tool used to measure an individual's level of fatigue during usual daily activities over the past 7 days. Items are scored on a 0-4 response scale (4=not at all to 0=very much) where the total possible score ranges from 0-52 (all items are summed up to create the total score); A score of less than 30 indicates severe fatigue. The higher scores represent better HRQoL.
Time frame: Baseline (Week 1), Week 2, 3, 5, 13, 27 and 53
Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire (Physical (PS), Mental Score (MS) and Alternative Scoring (PS-QM))
SF36 questionnaire is a tool to measure health-related QoL. SF36 questionnaires (physical and mental score) were answered throughout the study and is a validated instrument with 36 questions to measure general physical and mental health status via assessment of 8 domains-Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health-over the past 4 weeks. The SF36 is scored using norm-based scoring procedures and scores ranging from 0-100; higher values indicate less impairment, a higher QoL. In addition to this SAP-planned scoring score, an alternative scoring for both the physical SF36 score and the mental SF36 were performed by QualityMetric (QM) Incorporated, an IQVIA business.
Time frame: Baseline (Week 1), Week 2, 3, 5, 13, 27 and 53
Incidence and Severity of Bleeding Events
Incidence and severity of bleeding assessed by the modified World Health Organization (WHO) Bleeding Scale; Bleeding is graded based on a 1-4 scale (1=minor bleeding to 4=severe bleeding). Incidence of bleeding: participants had at least one bleeding event. Severity of bleeding: bleeding event is from grade 2 and higher
Time frame: Baseline up to 52 weeks
The study was conducted in 25 centers in Germany.
| Milestone | Eltrombopag + Dexamethasone | Dexamethasone |
|---|---|---|
| Started | 13 | 13 |
| Randomized, not treated | 1 | 0 |
| Completed | 8 | 10 |
| Not completed | 5 | 3 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Non-response | 1 | 1 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Pregnancy | 0 | 1 |
Sustained response off treatment at 52 weeks is defined as maintenance of platelet count ≥ 30 × 10\^9/L after treatment discontinuation until Week 52 in the absence of bleeding events ≥ Grade II or use of any rescue medication at all visits until Week 52. Bleeding events ≥ Grade II are assessed by the modified World Health Organization (WHO) Bleeding Scale; Bleeding is graded based on a 1-4 scale (1=minor bleeding to 4=severe bleeding). Characteristics of bleeding events ≥ Grade II include: epistaxis ≥30 minutes, large purpura, joint bleeding, melanotic stool, hematemesis, gross hematuria, abnormal vaginal bleeding, hemoptysis, Visible blood in body cavity fluid, retinal bleeding, bleeding at invasive sites, bleeding requiring transfusion, bleeding associated with moderate or severe hemodynamic instability, fatal bleeding, CNS bleeding.
| Participants | Eltrombopag + Dexamethasone | Dexamethasone |
|---|---|---|
| Percentage of Patients With Sustained Response Off Treatment at 52 Weeks | 2 | 2 |
Overall response after treatment at week 52 was defined as maintenance of platelet count ≥ 30 x 109/L and ≥ 2-fold increase of screening platelet count after treatment discontinuation in the absence of bleeding event ≥ Grade II and no rescue therapy at all visits until Week 52. Bleeding events ≥ Grade II are assessed by the modified World Health Organization (WHO) Bleeding Scale; Bleeding is graded based on a 1-4 scale (1=minor bleeding to 4=severe bleeding). Characteristics of bleeding events ≥ Grade II include: epistaxis ≥30 minutes, large purpura, joint bleeding, melanotic stool, hematemesis, gross hematuria, abnormal vaginal bleeding, hemoptysis, Visible blood in body cavity fluid, retinal bleeding, bleeding at invasive sites, bleeding requiring transfusion, bleeding associated with moderate or severe hemodynamic instability, fatal bleeding, CNS bleeding.
| Participants | Eltrombopag + Dexamethasone | Dexamethasone |
|---|---|---|
| Percentage of Patients With Overall Response at Week 52 | 2 | 2 |
Duration of sustained response off treatment is defined as time of treatment discontinuation until platelet count \< 30 × 109/L or bleeding events ≥ Grade II or use of any rescue therapy. If sustained response remains, the interval was censored with the date of the last platelet assessment. Bleeding events ≥ Grade II are assessed by the modified World Health Organization (WHO) Bleeding Scale; Bleeding is graded based on a 1-4 scale (1=minor bleeding to 4=severe bleeding). Characteristics of bleeding events ≥ Grade II include: epistaxis ≥30 minutes, large purpura, joint bleeding, melanotic stool, hematemesis, gross hematuria, abnormal vaginal bleeding, hemoptysis, Visible blood in body cavity fluid, retinal bleeding, bleeding at invasive sites, bleeding requiring transfusion, bleeding associated with moderate or severe hemodynamic instability, fatal bleeding, CNS bleeding.
| Weeks | Eltrombopag + Dexamethasone | Dexamethasone |
|---|---|---|
| Duration of Sustained Response Off Treatment | 49.1 ± 0.0 | 45.7 ± 2.8 |
Overall response by week 4 is defined as platelet count ≥ 30 × 109/L and ≥ 2 fold increase of screening platelet count and absence of bleeding and no rescue therapy within the first 4 weeks
| Participants | Eltrombopag + Dexamethasone | Dexamethasone |
|---|---|---|
| Overall Response by Week 4 | 10 | 11 |
Complete Response by week 4 is defined as platelet count ≥ 100 × 109/L and absence of bleeding and no rescue therapy until week 4.
| Participants | Eltrombopag + Dexamethasone | Dexamethasone |
|---|---|---|
| Complete Response by Week 4 | 8 | 9 |
Absolute change in platelet count from pre-treatment or screening to baseline (week 1) and from pre-treatment / screening to 2, 4, 13, 27 and 53 weeks. If pre-treatment was necessary before inclusion, platelet count data performed directly before pre-treatment were used for study inclusion (screening value to be used for inclusion/exclusion check and for analysis as a covariate).
| G/L | Eltrombopag + Dexamethasone | Dexamethasone |
|---|---|---|
| Week 1 | 32.0 ± 44.3 | 23.2 ± 48.0 |
| Week 2 | 145.2 ± 151.9 | 80.7 ± 68.8 |
| Week 4 | 192.5 ± 165.8 | 92.0 ± 68.7 |
| Week 13 | 119.4 ± 115.9 | 143.0 ± 88.5 |
| Week 27 | 217.8 ± 126.5 | 141.2 ± 94.7 |
| Week 53 | 139.0 ± 88.0 | 141.7 ± 61.4 |
Relative change in platelet count from pre-treatment or screening to baseline (week 1) and from pre-treatment or screening to 2, 4, 13, 27, and 53 weeks. If pre-treatment was necessary before inclusion, platelet count data performed directly before pre-treatment were used for study inclusion (screening value to be used for inclusion/exclusion check and for analysis as a covariate).
| Percentage change in platelet counts | Eltrombopag + Dexamethasone | Dexamethasone |
|---|---|---|
| Week 1 | 347.9 ± 486.8 | 293.4 ± 418.4 |
| Week 2 | 5795.5 ± 9672.4 | 2028.2 ± 4382.0 |
| Week 4 | 11400.9 ± 16875.2 | 2865.4 ± 3805.4 |
| Week 13 | 8050.6 ± 12277.8 | 4725.7 ± 8418.2 |
| Week 27 | 13667.9 ± 15717.1 | 4381.1 ± 8195.2 |
| Week 53 | 9392.3 ± 11476.0 | 5612.1 ± 8300.7 |
Time to overall response is defined as time from starting study treatment to time of achievement of overall response. Overall response is defined as a platelet count ≥ 30 × 10\^9/L and ≥ 2 fold increase of baseline platelet count and absence of bleeding and no rescue therapy censored with the last visit date for patients not achieving overall response. Results of TOR are reported per Kaplan-Meier estimates.
| Weeks | Eltrombopag + Dexamethasone | Dexamethasone |
|---|---|---|
| Time to Overall Response (TOR) | 1.1 (0.0 to 4.1) | 1.0 (0.1 to 1.3) |
Time to complete response is defined as time from starting study treatment to time of achievement of complete response. Complete response is defined as a platelet count ≥ 100 × 109/L and absence of bleeding and no rescue therapy. Results of time to complete response are reported per Kaplan-Meier estimates.
| Weeks | Eltrombopag + Dexamethasone | Dexamethasone |
|---|---|---|
| Time to Complete Response | 1.1 (0.1 to NA) | 2.1 (0.6 to NA) |
Duration of overall or complete response (CR) is defined as time of achievement of overall or CR until loss of overall or CR. The duration of CR was calculated from the date of onset of CR until platelet count \< 100 x 109/L, or bleeding events ≥ Grade II (assessed by the modified World Health Organization (WHO) Bleeding Scale) or use of any rescue therapy, whatever was earlier. Bleeding is graded based on a 1-4 scale (1=minor bleeding to 4=severe bleeding). Characteristics of bleeding events ≥ Grade II include: epistaxis ≥30 minutes, large purpura, joint bleeding, melanotic stool, hematemesis, gross hematuria, abnormal vaginal bleeding, hemoptysis, Visible blood in body cavity fluid, retinal bleeding, bleeding at invasive sites, bleeding requiring transfusion, bleeding associated with moderate or severe hemodynamic instability, fatal bleeding, CNS bleeding. Results of duration of overall and complete response are reported per Kaplan-Meier estimates.
| Weeks | Eltrombopag + Dexamethasone | Dexamethasone |
|---|---|---|
| Median duration of overall response | 8.3 (0.3 to NA) | 3.6 (1.1 to NA) |
| Median duration of complete response | 9.7 (1.3 to NA) | 1.3 (0.9 to 6.1) |
The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) instrument is a 13-item validated tool used to measure an individual's level of fatigue during usual daily activities over the past 7 days. Items are scored on a 0-4 response scale (4=not at all to 0=very much) where the total possible score ranges from 0-52 (all items are summed up to create the total score); A score of less than 30 indicates severe fatigue. The higher scores represent better HRQoL.
| scores on a scale | Eltrombopag + Dexamethasone | Dexamethasone |
|---|---|---|
| Change from Baseline (BL) to Week 2 | -4.2 ± 9.6 | -4.5 ± 6.9 |
| Change from BL to Week | 1.0 ± 4.4 | -2.9 ± 5.1 |
| Change from BL to Week 5 | 1.2 ± 5.0 | -5.1 ± 6.9 |
| Change from BL to Week 13 | 0.3 ± 8.3 | 0.3 ± 2.8 |
| Change from BL to Week 27 | -3.6 ± 11.0 | -3.1 ± 7.7 |
| Change from BL to Week 53 | 2.7 ± 5.6 | -3.4 ± 5.4 |
SF36 questionnaire is a tool to measure health-related QoL. SF36 questionnaires (physical and mental score) were answered throughout the study and is a validated instrument with 36 questions to measure general physical and mental health status via assessment of 8 domains-Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health-over the past 4 weeks. The SF36 is scored using norm-based scoring procedures and scores ranging from 0-100; higher values indicate less impairment, a higher QoL. In addition to this SAP-planned scoring score, an alternative scoring for both the physical SF36 score and the mental SF36 were performed by QualityMetric (QM) Incorporated, an IQVIA business.
| scores on a scale | Eltrombopag + Dexamethasone | Dexamethasone |
|---|---|---|
| Change from Baseline (CBL) to Wk 2: Physical Score (PS) | 1.9 ± 4.6 | -3.3 ± 6.6 |
| CBL to Week 3: PS | 2.5 ± 5.8 | -1.4 ± 8.8 |
| CBL to Week 5: PS | 1.5 ± 6.2 | -2.7 ± 10.5 |
| CBL to Week 13: PS | 3.5 ± 9.9 | 0.3 ± 8.0 |
| CBL to Week 27: PS | 2.6 ± 14.7 | -0.9 ± 10.8 |
| CBL to Week 53: PS | 8.1 ± 11.8 | 0.3 ± 10.0 |
| CBL to Week 2: Mental Score (MS) | -0.8 ± 6.1 | -1.2 ± 7.6 |
| CBL to Week 3: MS | -2.0 ± 11.0 | -1.6 ± 9.7 |
| CBL to Week 5: MS | 0.1 ± 7.3 | -1.7 ± 11.5 |
| CBL to Week 13: MS | 3.3 ± 7.5 | 4.1 ± 7.4 |
| CBL to Week 27: MS | -1.4 ± 4.9 | -2.7 ± 7.4 |
| CBL to Week 53: MS | 2.1 ± 8.8 | 0.6 ± 5.7 |
| CBL to Week 2: PS-QM | 2.0 ± 4.1 | -3.3 ± 6.0 |
| CBL to Week 3: PS-QM | 3.4 ± 6.4 | -1.4 ± 7.8 |
| CBL to Week 5: PS-QM | 2.4 ± 6.0 | -2.7 ± 8.5 |
| CBL to Week 1: PS-QM | 4.1 ± 8.5 | 0.3 ± 7.6 |
| CBL to Week 27: PS-QM | 3.6 ± 12.4 | -1.0 ± 9.7 |
| CBL to Week 53: PS-QM | 6.2 ± 10.7 | 0.2 ± 9.4 |
Incidence and severity of bleeding assessed by the modified World Health Organization (WHO) Bleeding Scale; Bleeding is graded based on a 1-4 scale (1=minor bleeding to 4=severe bleeding). Incidence of bleeding: participants had at least one bleeding event. Severity of bleeding: bleeding event is from grade 2 and higher
| Participants | Eltrombopag + Dexamethasone | Dexamethasone |
|---|---|---|
| Incidence of Bleeding events | 10 | 12 |
| Incidence of Bleeding events with severity: ≥ grade 2 | 6 | 2 |
| Incidence of Bleeding events with severity: ≥ grade 3 | 2 | 1 |
Collected over Adverse events (AEs) are collected from the first dose of study treatment until end of study treatment plus 30 days post treatment for each patient. AEs reported in this record are from first dose of study treatment until 30 days after end of treatment for each patient, approx. 3 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eltrombopag + Dexamethasone | 0/12 (0%) | 5/12 (41.7%) | 11/12 (91.7%) |
| Dexamethasone | 1/13 (7.7%) | 5/13 (38.5%) | 13/13 (100%) |
| Event | Eltrombopag + Dexamethasone | Dexamethasone |
|---|---|---|
| Immune thrombocytopeniaBlood and lymphatic system disorders | 2/12 | 0/13 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/12 | 2/13 |
| Aplastic anaemiaBlood and lymphatic system disorders | 1/12 | 0/13 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 1/12 | 0/13 |
| Oesophageal stenosisGastrointestinal disorders | 1/12 | 0/13 |
| Herpes zosterInfections and infestations | 1/12 | 0/13 |
| PneumoniaInfections and infestations | 1/12 | 0/13 |
| B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/12 | 0/13 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/12 | 0/13 |
| Renal colicRenal and urinary disorders | 1/12 | 0/13 |
| Event | Eltrombopag + Dexamethasone | Dexamethasone |
|---|---|---|
| PyrexiaGeneral disorders | 1/12 | 4/13 |
| COVID-19Infections and infestations | 3/12 | 4/13 |
| HeadacheNervous system disorders | 2/12 | 4/13 |
| Abdominal painGastrointestinal disorders | 3/12 | 0/13 |
| ConstipationGastrointestinal disorders | 3/12 | 0/13 |
| DiarrhoeaGastrointestinal disorders | 3/12 | 3/13 |
| FatigueGeneral disorders | 2/12 | 3/13 |
| RashSkin and subcutaneous tissue disorders | 1/12 | 3/13 |
| NauseaGastrointestinal disorders | 2/12 | 1/13 |
| NasopharyngitisInfections and infestations | 2/12 | 1/13 |
The Full Analysis Set (FAS) consists of all patients to whom study treatment has been assigned by randomization.
| Age, Continuous(Years) | Eltrombopag + Dexamethasone | Dexamethasone | Total |
|---|---|---|---|
| Mean | 60.6 ± 14.5 | 45.3 ± 14.3 | 53.0 ± 16.1 |
| Sex: Female, Male(Participants) | Eltrombopag + Dexamethasone | Dexamethasone | Total |
|---|---|---|---|
| Female | 6 | 6 | 12 |
| Male | 7 | 7 | 14 |
| Race/Ethnicity, Customized(Participants) | Eltrombopag + Dexamethasone | Dexamethasone | Total |
|---|---|---|---|
| Caucasian | 12 | 12 | 24 |
| Other | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Oct 2020 to primary completion in Sep 2023, 35 months.
Results were first posted in Mar 2025, 1 year 5 months after primary completion.
Of 66 phase 2 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 35 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag
Purpura, Thrombocytopenic, Idiopathic →